Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
UnitedHealth Group Incorporated (NYSE:UNH), a $273 billion healthcare giant with annual revenues exceeding $410 billion, announced significant updates today in a filing with the Securities and Exchange Commission. According to InvestingPro analysis, the company maintains a GREAT financial health score despite its shares declining over 50% in the past six months. The company disclosed the cancellation of performance-based restricted stock units granted to its former CEO, Andrew Witty, following his retirement. The decision, made by the Compensation and Human Resources Committee of the Board of Directors, was mutually agreed upon by Mr. Witty and the company. Despite recent leadership changes, InvestingPro data shows UnitedHealth maintains strong fundamentals with a P/E ratio of 12.5 and has consistently raised dividends for 15 consecutive years.
Additionally, UnitedHealth Group held its 2025 Annual Meeting of Shareholders on June 2, 2025. The meeting saw participation from holders of 811,952,044 shares of common stock. Key outcomes from the meeting included the election of nine directors for a one-year term. Among those elected were Charles Baker and Timothy Flynn, with Baker receiving 746,667,016 votes in favor and Flynn receiving 651,303,141 votes in favor. With the stock currently trading below its InvestingPro Fair Value, investors seeking detailed analysis can access comprehensive valuation metrics and 12 additional ProTips through the platform.
Shareholders also participated in a non-binding advisory vote on executive compensation, which was approved with 451,227,441 votes in favor. Furthermore, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 762,684,177 votes in favor.
A shareholder proposal requesting a vote on excessive golden parachutes was not approved, receiving 94,676,898 votes in favor and 655,943,208 votes against.
These announcements were made as part of a regulatory filing with the SEC.
In other recent news, UnitedHealth Group has been at the center of several noteworthy developments. The company held its 2025 annual shareholder meeting, where shareholders re-elected the existing board and approved a cash dividend of $2.21 per share, to be paid on June 24, 2025. Analysts at Bernstein reiterated their Outperform rating for UnitedHealth, highlighting the strategic direction under the new CEO, Steve Hemsley, and setting a price target of $377. Meanwhile, Piper Sandler lowered their price target for the stock to $353, maintaining an Overweight rating, citing a strategic turnaround plan. KeyBanc also revised their price target to $400 from $450, though they kept an Overweight rating, suggesting current valuations may be overly pessimistic. TD Cowen maintained a Hold rating with a $308 price target, noting the cautious outlook for 2025 and the strategic plans for 2026. UnitedHealth’s recent Medicare Advantage bids focus on improving margins, reflecting the company’s ongoing efforts to adapt to increased care activity. The company’s strategic turnaround and pricing discipline are central themes as it navigates future challenges and opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.